A novel immunotherapy for Type 1 diabetes patients is in the works. The researchers made use of patients' own regulatory T cells called Tregs to limit the disease's attack on the beta cells and retain the system's infection-fighting capability.
A novel immunotherapy for Type 1 diabetes patients is in the works. The researchers made use of patients' own regulatory T cells called Tregs to limit the disease's attack on the beta cells and retain the system's infection-fighting capability.
Share this Article
Recommended